SARS-COV-2 and assisted reproduction: an update in 2022



Statement from the ESHRE COVID-19 Working Group Date of publication: 25 February 2022

The COVID-19 pandemic and its impact upon ART staff and services for patients have evolved since the last statement by the ESHRE COVID-19 working group (1,2). New SARS-CoV-2 variants with a different profile of infectivity and disease severity have become dominant and vaccination has been offered in all EU countries to both staff and patients, with excellent uptake in most of them. A return to the pre-COVID-19 normality is not yet in sight (3).

ESHRE previous statements and recommendations with regards to triage and testing have restricted applicability at present apart from their historic and educational value detailing the response to a progressive global emergency (1,2,4,5).

To maintain safe ART practices, ESHRE recommends that services follow regional and country-specific guidance and/or good clinical practice with regards to SARS-CoV-2 testing (PCR testing and others). Protective measures should be commensurate with the stage of the pandemic and medical recommendations from national and local health authorities.

With regards to vaccination, ESHRE recommends that, if available, men and women attempting to conceive through assisted reproduction receive the COVID-19 vaccine before starting treatment or at any time during the fertility treatment or pregnancy.

ESHRE recommends that access to fertility services to men and women should not depend on the availability of COVID-19 vaccines, nor on the personal decision of individual patients about vaccination.

References

- 1. SARS-COV-2 and service adaptation: an update (publication date 08 June 2021) (https://www.eshre.eu/Home/COVID19WG)
- 2. COVID-19 vaccination and assisted reproduction (publication date 08 June 2021) (https://www.eshre.eu/Home/COVID19WG)
- 3. European Centre for Disease Prevention and Control. Maps in support of the Council Recommendation on a coordinated approach to travel measures in the EU. Available via https://www.ecdc.europa.eu/en/covid-19/situation-updates/weekly-maps-coordinated-restriction-free-movement.
- 4. ART and COVID-19 A Statement from ESHRE. Phase 2: ESHRE guidance document on recommencing ART. (publication date 23 April 2020) (https://www.eshre.eu/Press-Room/ESHRE-News#COVID19P2)
- 5. ART and COVID-19 A Statement from ESHRE. Phase 3: Safe ART services during the third phase of the COVID-19 pandemic. (publication date: 14 October 2020) (https://www.eshre.eu/Press-Room/ESHRE-News#guidoct20)

Disclaimer

This guidance represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained.

ESHRE makes no warranty, express or implied, regarding the guidance and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein. While ESHRE makes every effort to compile accurate information and to keep it up-to-date, it cannot, however, guarantee the correctness, completeness, and accuracy of the guidance in every respect.

The advice expressed herein is not binding on professionals working in the field of human reproduction and embryology. Hence, this advice will never lead to the liability of ESHRE in case a professional is willing to implement it. Notwithstanding the foregoing, ESHRE will not be liable for indirect damages or consequential damage.

Copyright © European Society of Human Reproduction and Embryology - All rights reserved

The content of this ESHRE statement has been published for personal and educational use only. No commercial use is authorised. No part of the ESHRE statement may be translated or reproduced in any form without prior written permission of the ESHRE communications manager.